References
- Leith CP, Kopecky KJ, Chen IM, . Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1 and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. Blood 1999;94:1086–1099.
- van den Heuvel-Eibrink, van der Holt B, Burnett AK, . CD34-related coexpression of MDR1 and BCRP indicates a clinically resistant phenotype in patients with acute myeloid leukemia (AML) of older age. Ann Hematol 2007;86:329–337.
- Schaich M, Soucek S, Thiede C, . MDR1 and MRP1 gene expression are independent predictors for treatment outcome in adult acute myeloid leukemia. Br J Haematol 2004;128:324–332.
- Beck J, Handgretinger R, Dopfer R, . Expression of mdr1, mrp, topoisomerase IIα/β, and cyclin A in primary or relapsed states of acute lymphoblastic leukemias. Br J Haematol 1995;89:356–363.
- Pallis M, Turzanski J, Higashi Y, . P-glycoprotein in acute myeloid leukemia: therapeutic implications of its association with both a multidrug resistant and an apoptosis resistant phenotype. Leuk Lymphoma 2002;43:1221–1228.
- Mrózek K, Marcucci G, Paschka P, . Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for prognostically prioritized molecular classification?Blood 2007;109:431–448.
- Smeets ME, Raymakers RA, Vierwinden G, . Triggering noncycling hematopoietic progenitors and leukemic blasts to proliferate increases anthracycline retention and toxicity by down regulating multidrug resistance. Blood 1999;94:2414–2423.
- Marzac C, Teyssandier I, Calendini O, . Flt3 internal tandem duplication and P-glycoprotein functionality in 171 patients with acute myeloid leukemia. Clin Cancer Res 2006;12:7018–7024.
- Kottaridis PD, Gale RE, Langabeer SE, . Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors. Blood 2002;100:2393–2398.
- Uggla B, Stahl E, Wagsater D, . BCRP mRNA expression v. clinical outcome in 40 adult AML patients. Leuk Res 2005;29:141–146.
- Pfaffl MW, Horgan GW, Dempfle L. Relative expression software tool for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res 2002; 30:36–46.
- Kiyoi H, Ohno R, Ueda R, . Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain. Oncogene 2002;21:2555–2563.
- Small D. Targeting FLT3 for treatment of leukemia. Semin Hematol 2008;45:17–21.
- Hunter MH, Pallis M, Seedhouse CH, . The expression of P-glycoprotein in AML cells with FLT3 internal tandem duplication is associated with reduced apoptosis in response to FLT3 inhibitors. Br J Haematol 2004;127:26–33.
- Fine R, Chambers T, Sachs C. P-glycoprotein, multidrug resistance and protein kinase C. Oncologist 1996;1:261–268.